scholarly journals P231 Work productivity loss in perianal crohn’s disease

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S280-S281
Author(s):  
H Jlassi ◽  
M Sabbah ◽  
N Bellil ◽  
D Trad ◽  
A Ouakaa ◽  
...  

Abstract Background Few data exist on the socio-professional impact in patients with perianal Crohn’s disease, probably because the patient-doctor relationship is mainly focused on obtaining clinical, biological and endoscopic remission of the Crohn’s disease (CD). Our study aimed to evaluate the impacts of perianal Crohn’s disease on work productivity. Methods A prospective cross-sectional study including patients with CD followed in the Gastroenterology department between July and August 2020 was performed. Professional impact was assessed using Work Productivity and Activity Impairment questionnaire (WPAI) which is composed of 6 questions evaluating during the last seven days preceding the interview with the patient, the absenteeism, the presenteeism, the total decrease in productivity and the decrease in daily activities for health reasons. The results are multiplied by 100, expressed as a percentage of time lost. A higher percentage indicates greater depreciation and less productivity. Professional impact was compared in patients with perianal Crohn’s disease and controls without perianal symptoms. Results Thirty two patients were included. The mean age was 38.28 years [18–60] and the sex ratio was 1. Perianal manifestations were observed in 15 patients (44% of cases). Thirteen patients (41%) were in paid employment at the time of inclusion. CD was responsible for an average absenteeism of 30% ± 10.4% [0–80%] of the working time during the last seven days. An average percentage of work impairment defining the presenteeism was noted to be 52% ± 28% [0–80%] of working time. The overall average decline in productivity was estimated at 56% ± 22% [0–97%]. CD was responsible for an average restriction of 45% ± 33% [0–100%] of usual daily activities. By comparing the professional impact according to the presence or not of anoperineal lesions (APL), an association between the mean rate of activity restriction and the presence of APL (p = 0.04) was objectified. However, no significant association was noted in the other dimensions of the WPAI questionnaire. Conclusion According to our study, it appears that Crohn’s disease is a source of reduced work productivity especially in case of perianal manifestation. These results should be confirmed by larger studies.

2012 ◽  
Vol 13 (10) ◽  
pp. 1287-1293 ◽  
Author(s):  
Antonino Spinelli ◽  
Chiara De Cassan ◽  
Matteo Sacchi ◽  
Piero Bazzi ◽  
Silvio Danese ◽  
...  

2020 ◽  
pp. 1-13
Author(s):  
Niels Teich ◽  
Michael Bläker ◽  
Frank Holtkamp-Endemann ◽  
Eric Jörgensen ◽  
Andreas Stallmach ◽  
...  

<b><i>Introduction:</i></b> Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. <b><i>Methods:</i></b> We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. <b><i>Results:</i></b> Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period (<i>p</i> &#x3c; 0.0001). After 3 months of IFX therapy, work productivity and activity increased by an average of 12.6 and 17.1%, respectively. Patient’s clinical outcome was markedly improved as the total CD activity index (CDAI) sum score continuously decreased from baseline to month 24 and the mean score of the total inflammatory bowel disease questionnaire (IBDQ) changed substantially from 141 at baseline to 172 after 24 months of IFX treatment. Additionally, the number of work incapacity days declined. Recently, no new safety issues of IFX have been identified. <b><i>Conclusion:</i></b> In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.


2015 ◽  
Vol 30 (11) ◽  
pp. 1589-1591 ◽  
Author(s):  
Arianna Zefelippo ◽  
Stefano Costa ◽  
Flavio Caprioli ◽  
Ettore Contessini-Avesani

2020 ◽  
Vol 30 (05) ◽  
pp. 395-400
Author(s):  
Annika Mutanen ◽  
Mikko P. Pakarinen

AbstractThe incidence of Crohn's disease is increasing worldwide. The clinical course of childhood onset Crohn's disease is particularly aggressive with characteristic disease localization in the ileocecal region and colon, often associated with perianal disease. Severe complications of perianal disease include recurrent perianal sepsis, chronic fistulae, fecal incontinence, and rectal strictures that impair quality of life and may require fecal diversion. Care of patients with perianal Crohn's disease requires a multidisciplinary approach with systematic clinical evaluation, endoscopic assessment, and imaging studies followed by combined medical and surgical management. In this review, we provide an update of the epidemiology, pathophysiology, diagnostics, and management of perianal Crohn's disease in children and adolescents.


Sign in / Sign up

Export Citation Format

Share Document